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ABSTRACT
Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown etiology and is characterized 
by chronic progressive cholestasis with destruction of the small intrahepatic bile ducts and associated most 
commonly with antimitochondrial antibodies. PBC is most common in women and is often associated with 
other autoimmune disease such as autoimmune hemolityc anemia (AIHA), rheumatoid arthritis, thyroiditis, 
and systemic lupus eritomatosus.
We report one case, a 20 years old woman with AIHA have been treated by corticosteroid since last year 
and she came to the outpatient department (OPD) with fatique and jaundice. The result of laboratory were 
haemoglobin 8.7 mg/dL, white blood cell 8700 mg/dL, coomb test +2, total bilirubin 33.2 mg/dL, direct bilirubin 
29.3 mg/dL, γGT: 297 mg/dL and alkalyphospatase: 158 mg/dL. The result of Abdominal CT scan showed the size 
of liver and spleen increased and normal common bile duct (CBD). The result of ANA test, anti-nuclear (ANA) 
and antimitochondrial M2 (AMA M2) antibodies were positive. From the physical examination, laboratory and 
CT scan Abdomen; the diagnose of this patient was AIHA with PBC. 
After treatment with corticosteroid (prednison 1mg/kg/day) and ursodeoxicholic acid (UDCA) for several 
weeks, the clinical manifestation of PBC such as jaundice getting better (the laboratory result: total bilirubin 
2.7 mg/dL, direct bilirubin 1.5 mg/dL, gamma GT 80 mg/dL).
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ABSTRAK
Primary biliary cirrhosis (PBC) adalah suatu penyakit hati autoimun yang etiologinya belum diketahui 
dan ditandai oleh kolestasis progresif yang kronik dengan kerusakan duktus bilier intra-hepatik dan umumnya 
dihubungkan dengan antibodi antimitokondrial. Pada umumnya PBC terjadi pada wanita dan biasanya 
berhubungan dengan penyakit autoimun lainnya, seperti anemia hemolitik autoimun (AIHA), artritis reumatik, 
tiroiditis dan eritema lupus sistemik.
Kami melaporkan sebuah kasus, wanita berumur 20 tahun dengan penyakit AIHA yang telah mendapat 
terapi kortikosteroid sejak 1 tahun lalu dan datang berobat di poli rawat jalan dengan lemah dan kuning seluruh 
badan. Hasil pemeriksaan laboratorium adalah hemoglobin 8.7 mg/dL, lekosit 8700 mg/dL, coomb test +2, 
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bilirubin total 33.2 mg/dL, bilirubin direk 29.3 mg/dL, γGT: 297 mg/dL dan alkaliphospatase: 158 mg/dL. Hasil 
pemeriksaan CT scan Abdomen menunjukkan adanya hepatosplenomegali dan duktus bilier dalam batas normal. 
Hasil pemeriksaan ANA tes didapatkan positif antibodi anti-nuclear (ANA) dan antibodi antimitokondrial M2 
(AMA M2). Dari hasil pemeriksaan fisis, laboratorium dan CT scan abdomen, maka kami mendiagnosis pasien 
ini dengan AIHA yang disertai dengan PBC.  
Setelah diberikan terapi kortikosteroid (prednison 1 mg/kg/hari) dan ursodeoxicholic acid (UDCA) selama 
beberapa minggu, manifestasi klinik dari PBC seperti kuning, menjadi berkurang (hasil laboratorium: bilirubin 
total 2.7 mg/dL, bilirubin direk 1.5 mg/dL, γGT 80mg/dL).
Kata kunci: primary biliary cirrhotic, anemia hemolitik autoimun, kortikosteroid, urosodeoxicholic acid
INTRODUCTION
Primary biliary cirrhosis (PBC) is an autoimmune 
liver disease of unknown etiology and is characterized 
by chronic progressive cholestasis with destruction of 
the small intrahepatic bile ducts and associated most 
commonly with antimitochondrial antibodies.1,2,3 The 
disease is uncommon, with a reported prevalence 
between 19 and 402 cases per million. The vast 
majority (90%) of patients affected are women, with 
the usual time of diagnosis between 30 and 60 years. 
The diagnosis of PBC is based on three criteria: 
elevation of liver enzymes (most commonly ALP and 
γ-GT), presence of detectable AMA in the serum, and 
liver histologic findings that are compatible with the 
presence of the disease.4
PBC is most common in women and is often 
associated with other autoimmune disease such as 
autoimmune hemolityc anemia (AIHA), rheumatoid 
arthritis, thyroiditis, and systemic lupus eritomatosus. 
Autoimmune hemolytic anemia involves an autoimmune 
process and is caused by a hemolysis induced by the 
reaction of autoantibodies with red blood cells (RBCs) 
and it’s characterized by a positive direct Coombs’ 
test. It is idiopathic (primary) in approximately 50% 
cases or secondary to medication, hematological 
malignancies and autoimmune disorders.5-9 AIHA is 
also a rare disease with incidences reported in the range 
of 1 per 75,000 to 2 per 100,000. Primary or idiopathic 
AIHA accounts for less than half of the cases and most 
patients will be found to have underlying associated 
conditions including tumors, autoimmune diseases, or 
an acquired immunodeficiency syndrome.9
The association between primary biliary cirrhosis 
(PBC) and autoimmune hemolytic anemia (AIHA) is 
uncommon. Despite the autoimmune basis of PBC, 
there have been few reports of PBC in association with 
AIHA.10 The recommended treatment for PBC-related 
AIHA includes sufficient doses of corticosteroids 
to control the hemolysis at the acute phase, and 
immunosuppressant (for example CTX and CsA) or 
adequate dose of UDCA to maintain therapy. 11 We 
describe a case of AIHA in association with PBC, 
which responded to ursodeoxycholic acid (UDCA) 
used as sole treatment.
CASE ILLUSTRATION 
We report a 20 years old woman with AIHA have 
been treated by corticosteroid since last year and she 
came to the outpatient department (OPD) with fatique 
and jaundice. From the physical examination, we found 
palor, hepatosplenomegaly, no lymphadenopathy. The 
result of laboratory were haemoglobin 8.7 mg/dL, 
white blood cell 8,700 mg/dL, coomb test +2, total 
bilirubin 33.2 mg/dL, direct bilirubin 29.3 mg/dL, γGT: 
297 mg/dL and alkalyphospatase: 158 mg/dL. Cause 
of jaundice, we did the Abdominal CT Scan. 
Figure 1. The abdominal CT scan’s results showed size of the 
liver and spleen increased with normal parenchyma, gallbladder 
within normal limited, no stone in CBD.
The result from ANA profile: anti-nuclear (ANA) 
and antimitochondrial M2 (AMA M2) antibodies were 
positive (Figure 2). Strong Positive in: SS-A native (60 
kDa): (+++); Ro-52 recombinant: (++); SS-B: (+++); 
Nucleosomes: (++); Control: (+++).
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After treatment with corticosteroid (prednison 
1mg/kg/day) and ursodeoxicholic acid (UDCA) for 
several weeks, the clinical manifestation of PBC such 
as jaundice getting better (the laboratory result: total 
bilirubin 2.7 mg/dL, direct bilirubin 1.5 mg/dL, gamma 
GT 80mg/dL).
DISCUSSION 
Primary biliary cirrhotic is a slowly progressive 
autoimmune disease. The diagnosis of PBC is based 
on three criteria: elevation of liver enzymes (most 
commonly ALP and γ-GT), presence of detectable 
AMA in the serum, and liver histologic findings that 
are compatible with the presence of the disease.9 While 
AIHA is also an immune disease which is caused 
by antibodies directed against autologous red cells, 
the diagnosis is based on the presence of anemia, 
signs of hemolysis with reticulocytosis, increased 
lactate dehydrogenase, elevated indirect bilirubin, 
and a positive Coombs’ test.2 Not all patients with 
PBC received the diagnosis when it was at an early 
stage because of their asymptomatic status, and it is 
supposed that PBC occurred after AIHA development 
Figure 2. The anti-nuclear (ANA) profile
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in these patients.9 The occurrence suggests a possible 
relationship between the two diseases. PBC patients 
are likely to have some conditions which can induce 
generation of anti-erythrocyte antibodies.8
Corticosteroid treatment is not only a preferred 
therapy for AIHA, but an adjuvant therapy that benefits 
PBC patients.11 According to the criteria of secondary 
AIHA: (1) AIHA would occur on the basis of PBC; 
(2) Reversal of AIHA and liver function improvement 
of PBC happened simultaneously with the intake 
of immunosuppressive agents; (3) Both PBC and 
AIHA are known to be immune-mediated diseases. 
Thus, we could call them PBC-related AIHA. Serum 
bilirubin levels have long been known to be important 
in assessing the prognosis of PBC, but confounding 
hemolysis may lead to erroneous conclusions about 
the severity of PBC.2 At the same time, compared 
with primary AIHA, this PBC-related AIHA is life-
threatening but can be controlled. If no attention is 
paid to this condition, primary PBC will be ignored, 
as 50–60% of PBC patients are asymptomatic at 
diagnosis.12 Therefore patients with PBC whose serum 
bilirubin levels rise suddenly should undergo screening 
for associated hemolysis.
The recommended treatment for PBC-related 
AIHA includes sufficient doses of corticosteroids 
to control the hemolysis at the acute phase, and 
immunosuppressant (for example CTX and CsA) 
or adequate dose of UDCA to maintain therapy. To 
deal with the severe, life-threatening hemolysis, 
intravenous immunoglobulin and large dosage of 
corticosteroids impact therapy may be considered. 
Only UDCA therapy for PBC patients with mild AIHA 
had a successful report, so in mild cases this method 
could be considered with regular blood cell counts to 
monitor response. Although Kaibori et al provided a 
successful case that could confirm liver transplantation 
and splenectomy is a curative therapy to PBC-related 
AIHA.5,8
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